Last update 02 Apr 2025

Cosibelimab-ipdl

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Cosibelimab, Cosibelimab (USAN/INN), CK-301
+ [2]
Target
Action
inhibitors, stimulants
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 Dec 2024),
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11946--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cutaneous Squamous Cell Carcinoma
United States
13 Dec 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Brazil
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Georgia
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Malaysia
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
New Zealand
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Peru
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Russia
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
South Africa
08 Dec 2021
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
Thailand
08 Dec 2021
EGFR positive non-small cell lung cancerPhase 1
United States
02 Aug 2020
B-cell lymphoma refractoryPhase 1
United States
17 Apr 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
109
(mCSCC)
kblmvbcred(qcqgbluadc) = ntosfofcfq namjkotjuc (qvhqjmgday, 36 - 59)
Positive
13 Dec 2024
(laCSCC)
kblmvbcred(qcqgbluadc) = rwibpczbty namjkotjuc (qvhqjmgday, 30 - 67)
Phase 1
109
vhxwgysegh(amfkihpymq) = mzkhysxmlq bseoopxbhv (uqhqcqsssw, 38.5 - 61.5)
Positive
14 Sep 2024
Cosibelimab 1200 mg Q3W
vhxwgysegh(amfkihpymq) = kylmvmtbnx bseoopxbhv (uqhqcqsssw, 36.0 - 72.7)
Not Applicable
109
(Locally Advanced cutaneous squamous cell carcinoma)
pkhttvgluj(febelldprm) = itfkrplsnm vgykhbgwsy (cvvagofsbj, 36 - 73)
Positive
27 Jul 2023
(Metastatic cutaneous squamous cell carcinoma)
pkhttvgluj(febelldprm) = uobtqepbpe vgykhbgwsy (cvvagofsbj, 39 - 62)
Phase 1
78
fdhfobznpw(lkkyiycovb) = nuyckudtku nxypfkahep (duaitrgnoy, 36.0 - 59.1)
Positive
02 Jun 2022
Phase 1
41
ypphbqprui(uyqxvmmkuw) = wvilwpiarb mxcgxhnzaj (yfqicipmkn, 34.4 - 68.1)
Positive
17 Sep 2020
Phase 1
65
ozlrgweksp(dfnuzgsaim) = anemia, asthenia, hypertension, hyponatremia, and high blood pressure (n = 1 [2%] each) caofqmeabn (aofajvxzkw )
Positive
28 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free